Books by Subject
- 2017 intravenous medications : a handbook for nurses and health professionals. Thirty-three edition [33rd ed.] — Handbook of pharmaceutical analysis (100)
- Handbook of pharmaceutical granulation technology. 2nd ed. — Polymers in drug delivery (100)
- Practical pharmaceutics : an international guideline for the preparation, care and use of medicinal products — Write it down : guidance for preparing effective and compliant documentation. 2nd ed. (38)
- 2005 CRCnetBASEedited by Dilip M. Parikh.
- v. 1-6, 2004. CRCnetBASEv. 2, 2004 CRCnetBASEv. 3, 2004 CRCnetBASEv. 4, 2004 CRCnetBASEv. 5, 2004 CRCnetBASEv. 6, 2004 CRCnetBASESarfaraz K. Niazi.v. 1. Compressed solid products -- v. 2. Uncompressed solid products -- v. 3. Liquid products -- v. 4. Semisolid products -- v. 5. Over-the-counter products -- v. 6. Sterile products.
- 2007 CRCnetBASEDaryl S. Paulson.
- Handbook of topical antimicrobials : industrial applications in consumer products and pharmaceuticals2003 CRCnetBASEedited by Daryl S. Paulson.
- 2015American Society of Health-System Pharmacists®.
- 2012 SpringerDevi Datt Joshi.Evidence based herbal drugs are on hi-acceptance day by day due to health friendly nature compared to synthetic drugs. The active ingredients in herbal drugs are different chemical classes, e.g. alkaloids, coumarins, flavonoids, glycosides, phenols, steroids, terpenes etc., are identified at molecular level using current analytical practices, which are unique characteristic, as finger, so known as fingerprints. The fingerprints are used for assessment of quality consistency and stability by visible observation and comparison of the standardized fingerprint pattern, have scientific potential to decipher the claims made on these drugs for authenticity and reliability of chemical constituents, with total traceability, which starts from the proper identification, season and area of collection, storage, their processing, stability during processing, and rationalizing the combinational in case of polyherbal drugs. These quality oriented documents have ample scientific logics so well accepted globally by regulatory authorities and industries, to determine intentional/ unintentional contamination, adulteration, pollutants, stability, quality, etc. parameters. Based on geo-climatic factors, a same plant species has different pharmacological properties due to different ingredients; such regional and morphological variations are identified by fingerprints, at the time of collection of the medicinal herb. The chromatographic (TLC, HPTLC, HPLC, GC,) and spectral (UV-Vis., FTIR, MNR, MS, LC-MS, GC-MS etc.) techniques have world-wide strong scientific approval as validated methods to generate the fingerprints of different chemical classes of active ingredients of herbal drugs. Presently there is a need for a book having all the fingerprinting techniques for herbal drugs at a place with theory, case studies and art to discover patentable forms. The present book is a mile stone in the subject, to be utilized by Scientists, Medical Doctors, Technicians, Industrialists, Researchers, and Students both in PG and UG levels.
- 2006 CRCnetBASEedited by Y.W. Francis Lam, Shiew-Mei Huang, Stephen D. Hall.
- 2009 CRCnetBASEedited by Perry G. Wang.High throughput sample preparation techniques and their application to bioanalytical protocols and purification of combinatorial libraries / Krishna Kallury -- High-throughput quantitative bioanalysis / Katty X. Wan -- Optimizing LCMS equipment to increase throughput in pharmaceutical analysis / Michael G. Frank and Douglas E. Mcintyre -- Throughput improvement of bioanalytical LC-MS/MS by sharing of detector between HPLC systems / Min Shuan Chang and Tawakol El-Shourbagy -- High throughput strategies for metabolite identification in drug discovery / Patrick J. Rudewicz, Qin Yue, and Young Shin -- Utilizing micro parallel liquid chromatography for high-throughput analyses in the pharmaceutical industry / Sergio A. Guazzotti -- Strategies and techniques for higher throughput ADME/PK assays / Walter Korfmacher -- High-throughput analysis in drug metabolism during early drug discovery / Yau Yi Lau -- High-throughput analysis in the support of process chemistry and formulation research & development in the pharmaceutical industry / Zhong Li -- On-line SPE LC/MS/MS for high throughput bioanalytical analysis / Dong Wei and Liyu Yang -- Applications of high-throughput analysis in therapeutic drug monitoring / Quanyun A. Xu and Timothy L. Madden -- High-throughput quantitative pharmaceutical analysis in drug metabolism and pharmacokinetics (DMPK) using liquid crhomatrography-mass spectrometry / Xiaohui Xu -- Designing high throughput HPLC assays for small and biological molecules / Roger K. Gilpin and Wanlong Zhou -- The advances in capillary and nano-HPLC technology for drug discovery and development / Frank J. Yang and Richard Yu -- High-throughput analysis of complex protein mixtures by mass spectrometry / Kojo S.J. Elenitoba-Johnson.
- 2008 CRCnetBASEedited by Tushar Kshirsagar.Application of parallel synthesis to the optimization of inhibitors of the ZipA-FtsZ protein-protein interaction / Lee D. Jennings -- Case studies of parallel synthesis in hit identification, hit exploration, hit-to-lead, and lead optimization programs / Alexander Ernst and Daniel Obrecht -- A successful application of parallel synthesis to computer-assisted structural optimization of new leads targeting human immunodeficiency virus-1 reverse transcriptase : the case of acylthiocarbamates and thiocarbamates / Angelo Ranise, Andrea Spallarossa, and Sara Cesarini -- How high-throughput medicinal chemistry can expedite lead discovery, lead optimization, and beyond / Rongshi Li -- Rapid lead identification of inhibitors of adenine nucleotide translocase: a case study of applying combinatorial chemistry techniques in drug discovery / Yazhong Pei, Walter H. Moos, and Soumitra Ghosh -- Parallel synthesis of anticancer, antiinflammatory, and antiviral agents derived from L- and D-amino acids / Robert C. Reid and David P. Fairlie -- Application of solid-phase parallel synthesis in lead optimization studies / Bijoy Kundu -- High-throughput solid-phase synthesis of nucleoside-based libraries in the search for new antibiotics / Dianqing Sun and Richard E. Lee.
- v. 1, 1954.by G.P. Srivastava ; with a foreword from George Urdang.
- 2007Howard Brody.The Good, the bad, and the ugly : a story of two medications -- An Ethical framework -- The Pharmaceutical industry and the free market -- Patents, generic drugs, and academic science -- Research and profits -- Suppression of research data -- The Quality of pharmaceutical research -- The Drug rep: historical background -- The Drug rep today -- The Influence of drug reps: what the data show -- Continuing medical education -- Professional organizations and journal advertising -- The Industry and the consumer -- The FDA: from patent medicines to AIDS drugs -- The FDA and the industry, 1990-2004 -- Solutions: the management and divestment strategies -- Solutions requiring enhanced professionalism in medicine -- Solutions requiring regulatory reform.Also available: Print – 2007
- 2014 SpringerPeter Timmins, Samuel R. Pygall, Colin D. Melia, editors.This detailed volume addresses key issues and subtle nuances involved in developing hydrophilic matrix tablets as an approach to oral controlled release. It brings together information from more than five decades of research and development on hydrophilic matrix tablets and provides perspective on contemporary issues. Twelve comprehensive chapters explore a variety of topics including polymers (hypromellose, natural polysaccharides and polyethylene oxide) and their utilization in hydrophilic matrices, critical interactions impacting tablet performance, in vitro physical and imaging techniques, and microenvironmental pH control and mixed polymer approaches, among others. In one collective volume, Hydrophilic Matrix Tablets for Oral Controlled Release provides a single source of current knowledge, including sections of previously unpublished data. It is an important resource for industrial and academic scientists investigating and developing these oral controlled release formulations.
- 2012 ScienceDirectDennis K. Flaherty.With a new pharmacy-specific approach to immunology, Immunology for Pharmacy prepares pharmacists for practice by providing a complete understanding of the basis of immunology and the consequences of either suppressing or enhancing immune function. It covers key subjects such as prophylaxis and vaccination, antibodies as therapeutic and diagnostic agents, biological modifiers, and the rationale for use and mechanisms of therapeutic agents. Written by experienced author and educator Dennis Flaherty, this book presents topics with a logical, step-by-step approach, explaining concepts and their practical application. A companion Evolve website reinforces your understanding with flashcards and animations. Pharmacy-specific coverage narrows the broad field of immunology to those areas most pertinent and clinically relevant to pharmacy students. 165 full-color illustrations help to illuminate difficult concepts. Factors That Influence the Immune Response chapter covers biological agents including bacteria, viruses, and fungi, and their related toxins and how they relate to the immune system. Three chapters on vaccinations prepare you for this important part of the pharmacist's role by discussing cancer treatment with whole tumor vaccines, cell vaccines, and viral vector vaccines, describing other vaccines such as recombinant vaccines and plant vaccines, and examining how diseases such as diphtheria, whooping cough, and tetanus respond to vaccinations. A summary of drugs used in treating each condition helps you understand typical treatments and their immunological mechanisms, so you can choose proper treatments. Integrated information makes it easier to understand how various parts of the immune system work together, leading to a better understanding of immunology as a whole. A unique focus on practical application and critical thinking shows the interrelationship of concepts and makes it easier to apply theory to practice. Information on AIDS covers the identification and treatment of both strains of HIV as well as AIDS, preparing you for diseases you will see in practice. Unique student-friendly features simplify your study with learning objectives and key terms at the beginning of each chapter, bulleted summaries and self-assessment questions at the end of each chapter, and a glossary at the back of the book. Over 60 tables summarize and provide quick reference to important material. A companion Evolve website includes animations and pharmacy terminology flashcards.
- 2005 CRCnetBASEedited by Jeffrey S. Handen.
- 2013 SpringerStephen Goundrey-Smith.Over the last 30-40 years, information technology (IT) has revolutionized professional life for millions of people around the world. IT has reduced the need for bulk storage of paper records by organizations, has enabled automation of tasks that were previously repetitive and labor-intensive, and carry them out in a fast and accurate way, has enabled economies of scale, improved efficiencies and enabled new ways of working that were hitherto impossible. In parallel with the rise of IT during the last 40 years, the role of the pharmacist - and the society in which pharmacists work - has changed considerably. Pharmacists are no longer principally compounders of medicines, but they are still responsible for ensuring that the patient receives the correct medicine, ensuring that the patient understands why they should take their medicine, and helping the patient with taking the medicine and being concordant with therapy.Information Technology in Pharmacy: an Integrated Approach provides a concise and practical general introduction to pharmacy IT, discusses issues surrounding the adoption of technology and how technologies may be utlilized by the pharmacy profession to exercise new professional roles and achieve new professional aspirations. This book will be of prime interest to practicing pharmacists at all levels, pharmacy students and pharmacy educators, but also to health informaticians, hospital and health care system administrators.
- 2005 CRCnetBASEedited by Diane J. Burgess.
- 2006 CRCnetBASETerry Mills, III, James Conrad Roberson, Christian C. Matchett, Mathew J. Simon, Mark D. Burns, Robert J. Ollis, Jr.V. 1. Acebutolol -- Dapsone -- v. 2. Dauromycin -- Indigotin Disulfonate -- v. 3. Indole-3-Acetic Acid -- Phendimetrazine -- v. 4. Phenelzine -- Zoxazolamine -- v. 5. Raman spectra data -- Mass spectra of pesticides -- Mass spectra of derivatized drugs -- Gas chromatography/infrared spectra of drugs -- v. 6. Standard KBr infrared spectra and standard NMR solvent spectra -- Supplemental infrared spectra -- Supplemental NMR spectra -- Ultraviolet absorption maxima -- Infrared index -- Mass spectra indices of drugs -- Mass spectra indices of pesticides -- Molecular formula index -- Gas chromatographic data -- Index to specific compounds.
- 2002 CRCnetBASEedited by Houng-Yau Mei, Anthony W. Czarnik.
- 2014 SpringerJoanna T. Brougher.Introduction to intellectual property -- Obtaining, enforcing and defending patents -- The patent-eligibility of genes -- Medical procedure patents -- Rights and roles of universities and inventors -- Drug development : balancing innovation, access and profits -- Patent battles part I : small-molecule drugs -- Patent battles part II : the Biosimilars Act and biologics -- International patent law, trade law, and access to drugs.
- Introduction to biological and small molecule drug research and development : theory and case studies2013 ScienceDirectedited by Robin Ganellin, Stanley Roberts, Roy Jefferis.Chapter 1. Introduction to enzymes, receptors and the action of small molecule drugs -- chapter 2. Protein structure and function -- chapter 3. The small molecule drug discovery process : from target selection to candidate selection -- chapter 4. Protein therapeutics (introduction to biopharmaceuticals) -- chapter 5. Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics -- chapter 6. Therapies for type 2 diabetes : modulating the incretin pathway using small molecule peptidase inhibitors or peptide mimetics -- chapter 7. The structure and business of biopharmaceutical companies including the management of risks and resources -- chapter 8. Discovery and development of the anticancer agent gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase -- chapter 9. Targeting HER2 by monoclonal antibodies for cancer therapy -- chapter 10. Recombinant human erythropoietin and its analogues -- chapter 11. Lysosomal storage disorders : current treatments and future directions -- chapter 12. Hormone replacement therapy -- chapter 13. Design of the anti-HIV protease inhibitor darunavir -- chapter 14. The case of anti-TNF agents -- chapter 15. Discovery of the cholesterol absorption inhibitor, ezetimibe.
- Isoquinolines and beta-carbolines as neurotoxins and neuroprotectants : new vistas In Parkinson's disease therapy2012 SpringerLucyna Antkiewicz-Michaluk, Hans Rommelspacher, editors.
- 2006 ScienceDirectby Graham Dukes.
- 2010 Springer Protocolsedited by Ana Cećilia A. Roque.Part I. Reviews -- 1. An Historical overview of drug discovery / Ana Sofia Pina, Abid Hussain, and Ana Cecília Roque -- 2. Ligand macromolecule interactions : theoretical principles of molecular recognition / Tammy Nolan, Nidhi Singh, and Christopher R. McCurdy -- 3. X-Ray cystallography in drug discovery / Ana Luísa Carvalho, José Trincão, and Maria João Romão -- 4. Virtual screening of compound libraries / Nuno M.F.S.A. Cerqueira, Sérgio F. Sousa, Pedro A. Fernandes, and Maria João Ramos -- Part II: Protocols -- 5. Combinatorial chemistry and the synthesis of compound libraries / Rolf Breinbauer and Matthias Mentel -- 6. Ligand-based nuclear magnetic resonance screening techniques / Aldino Viegas, Anjos L. Macedo, and Eurico Cabrita -- 7. Isothermal titration calorimetry and differential scanning calorimetry / Geoff Holdgate -- 8. Adaptive combinatorial design of focused compound libraries / Gisbert Schneider and Andreas Schüller -- 9. Chemical microarrays : a new tool for discovery enzyme inhibitors / Shuguang Liang, Wei Xu, Kurumi Y. Horiuchi, Yuan Wang, and Haiching Ma -- 10. Fluorescence polarization and time-resolved fluorescence resonance energy transfer techniques for PI3K assays / Kurumi Y. Horiuchi and Haiching Ma -- 11. Small molecule protein interaction profiling with functional protein microarrays / Lihao Meng, Dawn Mattoon, and Paul Predki -- 12. Capillary electrophoresis in drug discovery / Milena Quaglia and Ersilia De Lorenzi -- 13. SPR in drug discovery : searching bioactive compounds in plant extracts / Maria Minunni and Anna Rita Bilia -- 14. Application of frontal affinity chromatography with mass spectrometry (FAC-MS) for stereospecific ligand-macromolecule interaction, detection and screening / Jacek Slon-Usakiewicz and Peter Redden -- 15. GPC spin column HPLC-ESI-MS methods for screening drugs noncovalently bound to proteins / Marshall M. Siegel -- 16. A scintillation proximity assay for fatty acid amide hydrolase compatible with inhibitor screening / Yuren Wang and Philip Jones -- 17. A natural products approach to drug discovery : probing modes of action of antitumor agents by genome-scale cDNA library screening / Hendrik Luesch and Pedro Abreu -- 18. Ligand-macromolecule interactions in live cells by fluorescence correlation spectroscopy / Aladdin Pramanik
- v. 1-3, 2007 CRCnetBASEv. 2, 2007 CRCnetBASEv. 3, 2007 CRCnetBASEedited by Gregory Gregoriadis.v. 1. Liposome preparation and related techniques -- v. 2. Entrapment of drugs and other materials into liposomes -- v. 3. Interactions of liposomes with the biological milieu.Also available: Print – v. 1-3., 2007
- 2005 CRCnetBASEedited by Claudio Nastruzzi.
- 2008 OvidAmy M. Karch.
- 2007 OvidAmy M. Karch.
- 2011 OvidAmy M. Karch.
- 2015 OvidAmy M. Karch.Patient Safety and Medication Administration -- Nursing Process Guidelines -- Pharmacologic Classes -- Alphabetical Listing of Drugs by Generic Name.
- 2012 OvidAmy M. Karch.
- 2012 SpringerJeremy C. Wright, Diane J. Burgess, editors.
- 2016 Springer[edited by] Maureen Mackintosh, Geoffrey Banda, Paula Tibandebage, Watu Wamae.Making medicines in Africa : an historical political economy overview / Geoffrey Banda, Samuel Wangwe, Maureen Mackintosh -- Pharmaceuticals in Kenya : the evolution of technological capabilities / Roberto Simonetti, Norman Clark -- Pharmaceutical manufacturing decline in Tanzania : how possible is a turnaround to growth? / Paula Tibandebage, Samuel Wangwe, Maureen Mackintosh -- Bringing industrial and health policies closer : reviving pharmaceutical production in Ethiopia / Tsige Gebre-Mariam, Kedir Tahir, Solomon Gebre-Amanuel -- South-south collaboration in pharmaceuticals : manufacturing antiretroviral medicines in Mozambique / Giuliano Russo, Lâicia de Oliveira -- Can foreign firms promote local production of pharmaceuticals in Africa? / Sudip Chaudhuri -- Raising the technological level : the scope for API, excipients, additives and biologicals manufacture in Africa / Joseph Fortunak, Skhumbuzo Ngozwana, Tsige Gebre-Mariam, Tiffany Ellison, Paul Watts -- Health systems as industrial policy : building collaborative capabilities in the Tanzanian and Kenyan health sectors and their local suppliers / Maureen Mackintosh, Paula Tibandebage, Joan Kariuki Kungu, Mercy Karimi Njeru, Caroline Israel -- The dissemination of local health innovations : political economy issues in Brazil / Erika Aragäao, Jane Mary Guimaräaes, Sebastiäao Loureiro -- Healthy industries and unhealthy populations : lessons from Indian problem-solving / Smita Srinivas -- Policies to control medicines prices : does the South African experience have lessons for other African countries? / Skhumbuzo Ngozwana -- African pharmaceutical standards : the road to improvement and their role in technological capability upgrading / Geoffrey Banda, Julius Mugwagwa, Dinar Kale, Margareth Ndomondo-Sigonda -- Innovative procurement for health and industrial development / Joanna Chataway, Geoffrey Banda, Gavin Cochrane and Catriona Manville -- Industry associations and the changing politics of making medicines in South Africa / Theo Papaioannou, Andrew Watkins, Julius Mugwagwa, Dinar Kale -- Finance and incentives to support the development of national pharmaceutical industries / Alastair West, Geoffrey Banda.
- 2002 CRCnetBASEedited by David T. Rossi and Michael W. Sinz.
- 2008 Wileyby John J. Tobin and Gary Walsh.
- 2005 MyiLibraryThomas Nogrady, Donald F. Weaver.Also available: Print – 2005
- 2012 CRCnetBASEeditors, Mahendra Rai, Geofffrey A. Cordell, Jose L. Martinez, Mariela Marinoff, Luca Rastrelli.New strategies for traditional medicine -- Developing better herbal medicines in the post-genomic era -- Revitalization of the knowledge of herbs: a way forward to discovery of new drugs -- Ethnobotanical uses of the native flora from Brazilian north-eastern region -- Diversity and uses of the genus croton (euphorbiaceae) in Northeastern Brazil -- Ethnomedical knowledge among the "Quilombolas" from the Amazon region of Brazil with a special focus on plants used as nervous system tonics -- Advances in the knowledge of medicinal plants in Eastern Andalusia, Spain -- Tropical propolis: recent advances in chemical components and Botanical origin -- Anti-malarial plants used in folk medicine in Bangladesh -- Usnea sulcata motyka: an ethnomycological review of its use in traditional medicine -- Sirukurinjan: An ancient remedy for a modern incurable disease, diabetes -- Herbal drugs used for domestic animals -- Endophytes from medicinal plants as novel sources of bioactive compounds -- Advances in medicinal plants with antitumoral activity -- Medicinal plants: how are they used to treat neurological diseases? -- Inflammatory diseases: mechanisms and natural remedies -- Recent advances to evaluate anti-diabetic medicinal plants -- Botanical origin and Biological activity of propolis -- Bioactivity of plant essential oils -- Antibacterial and antiviral effects of aromatic plant-derived essential oils: a scientific and medicinal approach -- Strategies of solvent system selection for the isolation of natural products by countercurrent chromatography.
- 1999-2006by Leonard D. Rosenman.A compilation of medicines and herbals taken from medieval texts, 1170 and 1325.
- 2013Maryadele J. O'Neil, editor-in-chief ; Patricia E. Heckelman, senior associate editor ; Peter H. Dobbelaar, associate editor ; Kristin J. Roman, assistant editor ; Catherine M. Kenny, senior editorial assistant ; Linda S. Karaffa, technical assistant.
- 2006 CambridgeSoftMaryadele J. O'Neil, editor ... [et al.].Also available: Print – 2006
- 2009 ClinicalKeyeditor, J.K. Aronson.Corticosteroids and related drugs -- Prostaglandins -- Sex hormones and related drugs -- Iodine and drugs that affect thyroid function -- Insulins and other hypoglycemic drugs -- Other hormones and related drugs -- Lipid-regulating drugs -- Endocrine and metabolic adverse effects of non-hormonal and non-metabolic drugs.
- 2010 ClinicalKeyeditor J.K. Aronson.Elsevier now offers a series of derivative works based on the acclaimed Meyler's Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician. Opioids and analgesics are members of a diverse group of drugs used to relieve pain. They are frequently used in combination with prescription and nonprescription pain relievers, and misuse is prevalent. Pain medicine specialists and most physicians or surgeons will find this volume useful in prescribing the appropriate drugs for pain therapy and for preventing mi.
- 2010 ClinicalKeyedited by Jeffrey K. Aronson.Antibacerial Drugs -- Antiviral Drugs, Including Immunoglobulins and Interferons -- Antifungal Drugs -- Antiprotozoal and Antihelminthic Drugs -- Vaccines -- Disinfectants and Antiseptics.
- 2009 ClinicalKeyeditor, J.K. Aronson.Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician. Each year, heart disease kills more people than cancer. Patients are treated by a variety of specialists and primary care practitioners, depending on the organ system involved. This volume enables practitioners to assess the adverse effects of the complete range of drugs used in cardiovascular medicine, including antihypertensive drugs, and drugs used in the treatment.
- 2010 ClinicalKeyedited by Jeffrey K. Aronson.Drugs Used in Cancer Chemotherpy -- Corticosteroids and Prostaglandins -- Cytokines and Cytokine Modulators Interferons -- Monoclonal Antibodies -- Immune Modulators.
- 2009 ClinicalKeyeditor, J.K. Aronson.Antidepressants -- Neuroleptic Drugs -- Hypnosedatives -- Drugs of Abuse -- Drugs use in Alzheimer's Disease -- Psychological and Psychiatric Adverse Effects of Non-Psychoactive Drugs.
- 2013 Future Mededitor, Vladimir Krcméry.Antibiotic resistance : postantibiotic era is here / Vladimir Krcmery -- Current challenges in treating methicillin-resistant Staphylococcus aureus : what are the options? / Noha E.I. Sakka & Ian M . Gould -- Antimicrobial-resistant Streptococcus pneumoniae : trends and management / Michael R. Jacobs -- Emergence and management of drug-resistant enterococcal infections / William R. Miller, Barbara E. Murray & Cesar A. Arias -- Enterobacteriaceae that produce newer b-lactamases / Johann D.D. Pitout -- Extensively drug-resistant tuberculosis : new strains, new challenges / Megan Coffee -- Clinical significance of extended-spectrum b-lactamases / Jesés Rodréguez-Baño, Belén Gutiérrez, Lorena Lépez-Cerero & Alvaro Pascual -- Plasmid-mediated quinolone resistance / José Manuel Rodréguez-Marténez, Maréa Eliecer Cano, Jorge Calvo, Álvaro Pascual & Luis Marténez-Marténez -- Antibiotic resistance in the absence of antimicrobial use / Lucia Pallecchi, Alessandro Bartoloni, Eduardo Gotuzzo & Gian Maria Rossolini -- Resistance in bacteria of the food chain : epidemiology and control strategies / Lina Maria Cavaco & Frank Møller Aarestrup -- Measures to prevent antimicrobial resistance / Vhairi M. Bateman & Ian M. Gould -- Where does novel antibiotics R&D stand among other pharmaceutical products? / Glenn S. Tillotson -- Resistance to antiretroviral drugs / Manuela Colafigli, Simona Di Giambenedetto & Roberto Cauda -- Index.
- 2013 SpringerMarkus Müller, editor.In vivo target site concentrations are probably the most important determinant of drug effects. Traditionally, linking drug concentrations to drug effects has been accomplished by modelling blood-derived data, mostly because a direct quantification of tissue concentrations has been beyond technical reach. Today, a direct measurement of target site concentrations is possible by employing microdialysis or complementary approaches such as imaging technologies. Microdialysis, initially conceived in the 1970s, has become a standard tool in drug development. This comprehensive overview of current microdialysis technology covers general and disease-specific aspects of microdialysis by international experts in the field. It provides useful information for colleagues in academia and industry who are interested PK-PD aspects of drug development.
- 2006 CRCnetBASEedited by Simon Benita.
- 2012 SpringerNiall Barron, editor."MicroRNAs are small, non-coding RNA molecules that interact with target mRNAs to modulate their translation. They are now recognized as widespread and critical regulators of gene expression in the cell. This book is aimed at both industry- and academic-based researchers in the Biopharmaceutical production space who wish to learn more about these fascinating molecules..."--Page  of cover.
- 2013 CRCnetBASEGuanghui Ma, Zhiguo Su.1. Microspheres for enzyme immobilization / Fei Gao, Yuxia Wang, and Guanghui Ma -- 2. Microspheres for cell culture / Weiqing Zhou, Guanghui Ma, and Zhiguo Su -- 3. Microcapsules for cell transplantation : design, preparation, and application / Guojun Lv, Ying Zhang, Mingqian Tan, Hongguo Xie, and Xiaojun Ma -- 4. Microspheres for the separation and refolding of proteins with an emphasis on particles made of agarose / Jan-Christer Janson -- 5. Microspheres for separation of bioactive small molecules / Fangling Gong, Guifeng Zhang, and Zhiguo Su -- 6. Microspheres for separation of PEG-modified biomolecules / Yongdong Huang, Yanqin Zhai, and Zhiguo Su -- 7. Microspheres for solid-phase organic synthesis / Jing Zhang and Zhiguo Su -- 8. Microspheres for solid-phase modification of proteins / Tao Hu and Zhiguo Su -- 9. Microspheres and microcapsules for protein drug delivery / Lianyan Wang, Tingyuan Yang, and Guanghui Ma -- 10. Micro/nanospheres for gene drug delivery / Jie Wu and Guanghui Ma -- 11. Microspheres for targeting delivery of anticancer drugs / Wei Wei, Zhanguo Yue, Hua Yue, and Guanghui Ma -- 12. Microspheres for targeting delivery to brain / Chen Jiang, Xinguo Jiang, Yang Liu, Kun Shao, and Rongqin Huang -- 13. Nano/microspheres in bioimaging and medical diagnosis / Xiaohui Li and Chunying Chen -- 14. Affinity nanoparticles for detection / Haruma Kawaguchi and Hiroshi Handa.
- 2002 CRCnetBASEedited by Gilbert S. Banker, Christopher T. Rhodes.
- 2003 CRCnetBASEedited by Michael J. Rathbone, Jonathan Hadgraft, Michael S. Roberts.
- 2012 CRCnetBASEedited by Beena Rai."Preface Over the past few decades, molecular modeling (MM) has become an important tool in many academic institutions and industrial laboratories. While the role of MM in biological fields--especially in the design and development of novel drug molecules or formulations--is well established and acknowledged, its direct role in the design and development of performance chemicals and novel materials is still not well known. Questions such as, which new products have resulted from an MM-based approach? are still often asked. Although MM may be playing an important role in product development, quite often it becomes difficult to predict its direct impact because most of the time the problem being addressed involves a multidisciplinary approach. Further, the assumption that fundamental phenomena being modeled though MM will have a direct impact on the macroscopic and functional properties of a product make the situation more complicated. In most of the cases, MM actually works as an enabler toward novel product and material development (e.g., novel drug molecules in biological application) rather than directly coming up with new products and materials. This precisely is the reason that despite seeing value in MM tools, most engineers and practitioners are often focus on the question, how do I leverage these tools to design and develop novel materials or chemicals for the industry I am working with? Unfortunately, there is no simple answer to this question. Excellent books and very good research publications highlight the most intricate, fundamental, and theoretical details about MM techniques and tools"-- Provided by publisher.
- 2003 CRCnetBASEedited by György Kéri and István Toth.
- 2011 CRCnetBASEMark Chang."Preface Drug development, aiming at improving people's health, becomes more costly every year. The pharmaceutical industry must join its efforts with government and health professions to seek new, innovative, and cost- effective approaches in the development process. During this evolutionary process in the next decades, computer simulations will no doubt play a critical role. Computer simulation or Monte Carlo is the technique of simulating a dynamic system or process using a computer program. Computer simulations, as an efficient and effective research tool, have been used virtually in every concern of engineering, science, mathematics, etc. In this book, I am going to present the concept, theory, algorithm, and cases studies of Monte Carlo simulation in the pharmaceutical and health industries. The concepts refer not only to simulation in general, but also to various types of simulations in drug development. The theory will include virtual data sampling, game theory, deterministic and stochastic decision theories, adaptive design methods, Petrinet, genetic programming, resampling methods, and other strategies. These theories and methods either are necessary to carry out the simulations or make the simulations more efficient, even though there are many practical problems that can be simulated directly in ad hoc fashion without any theory of their efficiency or convergence considerations. The algorithms, which can be descriptive, computer pseudocode, or a combination of both, provide the basis for implementation of simulation methods. The case studies or applications are the simplified versions of the real world problems. These simplifications are necessary because a single case could otherwise occupy the whole book, preventing readers from exploring broad issues"--Provided by publisher.
- 2014 ClinicalKeyArthur H. Jeske [editor].Ideal for chairside use by the entire dental team, Mosby's Dental Drug Reference, 11th Edition, provides the current, concise, dental-specific drug information you need at the point of care. More than 850 drug monographs make it easy to find indications and dosages, contraindications, interactions, side effects, serious reactions, and dental considerations. A companion website adds regular drug updates, a full-color pill atlas, printable patient education handouts, reference tables, and more. More than 850 drug monographs offer the vital dental-specific drug information you need.Drug information with relevant patient and family education guidelines in each monograph emphasize oral health, prevention, and treatment from the dental hygiene perspective.Durable and pocket sized, a succinct and organized format makes this guide ideal for chairside use. Bulleted lists provide quick and easy access to general and specific dental-related information in each monograph. .Primers on therapeutic management of common diseases and on medically compromised patients offer key foundational information relevant to the treatment of all patients.New monographs, FDA updates, a color pill atlas, images of common pathologic conditions, patient education handouts, quick-reference guides, and more are available online to help keep this guide compact and user-friendly.
- 2010 CRCnetBASEedited by Alex Dmitrienko, Ajit C. Tamhane, Frank Bretz.1. Multiplicity problems in clinical trials : a regulatory perspective / Mohammad Huque and Joachim Rèohmel -- 2. Multiple testing methodology / Alex Dmitrienko ... [et al.] -- 3. Multiple testing in dose-response problems / Frank Bretz, Ajit C. Tamhane, and Josâe Pinheiro -- 4. Analysis of multiple endpoints in clinical trials / Ajit C. Tamhane and Alex Dmitrienko -- 5. Gatekeeping procedures in clinical trials / Alex Dmitrienko and Ajit C. Tamhane -- 6. Adaptive designs and confirmatory hypothesis testing / Willi Maurer, Michael Branson, and Martin Posch -- 7. Design and analysis of microarray experiments for pharmacogenomics / Jason C. Hsu ... [et al.].
- 2007 CRCnetBASEedited by Deepak Thassu, Michel Deleers, Yashwant Pathak.Nanoparticulate drug-delivery systems: an overview / Deepak Thassu, Yashwant Pathak and Michel Deleers -- Nanosuspensions for parenteral delivery / Barrett E. Rabinow -- Nanoparticles prepared using natural and synthetic polymers / Sudhir S. Chakravarthi, Dennis H. Robinson and Sinjan De -- Nanofiber-based drug delivery / Matthew D. Burke and Dmitry Luzhansky -- Drug nanocrystals - the universal formulation approach for poorly soluble drugs / Jan Möschwitzer and Rainer H. Müller -- Lipid-based nanoparticulate drug delivery systems / Jun Wu, Xiaobin Zhao and Robert J. Lee -- Nanoengineering of drug delivery systems / Ashwath Jayagopal and V. Prasad Shastri -- Aerosol flow reactor method for the synthesis of multicomponent drug nano- and microparticles / Janne Raula ... [et al.] -- Supercooled smectic nanoparticles / Heike Bunjes and Judith Kuntsche -- Biological and engineering considerations for developing tumor-targeting metallic nanoparticle drug-delivery systems / Giulio F. Paciotti and Lawrence Tamarkin -- Biological requirements for nanotherapeutic applications / Joseph F. Chiang -- Role of nanobiotechnology in the development of nanomedicine / K.K. Jain -- Pharmaceutical applications of nanoparticulate drug-delivery systems / Yashwant Pathak, Deepak Thassu and Michel Deleers -- Lipid nanoparticles (solid lipid nanoparticles and nanostructured lipid carriers) for cosmetic, dermal, and transdermal applications / Eliana B. Souto and Rainer H. Müller -- Nano-carriers of drugs and genes for the treatment of restenosis / Einat Cohen-Sela ... [et al.] -- Ocular applications of nanoparticulate drug-delivery systems / Annick Ludwig -- Nanoparticulate systems for central nervous system drug delivery / Jean-Christophe Olivier and Manuela Pereira de Oliveira -- Nanoparticles for gene delivery: formulation characteristics / Jaspreet K. Vasir and Vinod Labhasetwar -- Gastrointestinal applications of nanoparticulate drug-delivery systems / Maria Rosa Gasco -- Nanoparticles as adjuvant-vectors for vaccination / Socorro Espuelas ... [et al.] -- Transdermal applications of nanoparticulates / Jongwon Shim.
- 2016 SpringerUlrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch, editors.This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
- 2012 SpringerMark A. Geyer, Gerhard Gross, editors.This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
- 2013 SpringerDebmalya Barh, Dipali Dhawan, Nirmal Kumar Ganguly, editors.Omics for Personalized Medicine will give to its prospective readers the insight of both the current developments and the future potential of personalized medicine. The book brings into light how the pharmacogenomics and omics technologies are bringing a revolution in transforming the medicine and the health care sector for the better. Students of biomedical research and medicine along with medical professionals will benefit tremendously from the book by gaining from the diverse fields of knowledge of new age personalized medicine presented in the highly detailed chapters of the book. The book chapters are divided into two sections for convenient reading with the first section covering the general aspects of pharmaocogenomic technology that includes latest research and development in omics technologies. The first section also highlights the role of omics in modern clinical trials and even discusses the ethical consideration in pharmocogenomics. The second section is focusing on the development of personalized medicine in several areas of human health. The topics covered range from metabolic and neurological disorders to non-communicable as well as infectious diseases, and even explores the role of pharmacogenomics in cell therapy and transplantation technology. Thirty-four chapters of the book cover several aspects of pharmacogenomics and personalized medicine and have taken into consideration the varied interest of the readers from different fields of biomedical research and medicine. Advent of pharmacogenomics is the future of modern medicine, which has resulted from culmination of decades of research and now is showing the way forward. The book is an honest endeavour of researchers from all over the world to disseminate the latest knowledge and knowhow in personalized medicine to the community health researchers in particular and the educated public in general.
- 2011 SpringerDouglas J. Rhee, Kathryn A. Colby, Lucia Sobrin, Christopher J. Rapuano.Antibacterial agents -- Antifungal agents -- Antiviral agents -- Anti-parasitic agents -- Anti-glaucoma agents -- Neuro-ophthalmology -- Anti-inflammatory agents -- Mydriatics, cycloplegics, and reversal agents -- Lubricants and viscoelastics -- Miscellaneous -- Anti-angiogenesis agents -- Contact lens solutions.
- 2014 Springer Protocolsedited by Gary W. Caldwell and Zhengyin Yan, CREATe Analytical Sciences, Janssen Research & Development, LLS, Spring House, PA, USA.Thoroughly revised and updated, Optimization in Drug Discovery: In Vitro Methods, Second Edition presents a wide spectrum of in vitro assays including formulation, plasma binding, absorption and permeability, cytochrome P450 (CYP) and UDP-glucuronosyltransferases (UGT) metabolism, CYP inhibition and induction, drug transporters, drug-drug interactions via assessment of reactive metabolites, genotoxicity, and chemical and photo-mutagenicity assays. Written for the Methods in Pharmacology and Toxicology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and tips on troubleshooting and avoiding known pitfalls. Expert authors have developed and utilized these in vitro assays to achieve drug-like characteristics in addition to efficacy properties and good safety profiles of drug candidates. Comprehensive and up-to-date, Optimization in Drug Discovery: In Vitro Methods, Second Edition aims to guide researchers down the difficult path to successful drug discovery and development.
- 2013Alisha Rankin."Panaceia's Daughters provides the first book-length study of noblewomen's healing activities in early modern Europe. Drawing on rich archival sources, Alisha Rankin demonstrates that numerous German noblewomen were deeply involved in making medicines and recommending them to patients, and many gained widespread fame for their remedies. Turning a common historical argument on its head, Rankin maintains that noblewomen's pharmacy came to prominence not in spite of their gender but because of it. Rankin demonstrates the ways in which noblewomen's pharmacy was bound up in notions of charity, class, religion, and household roles, as well as in expanding networks of knowledge and early forms of scientific experimentation. The opening chapters place noblewomen's healing within the context of cultural exchange, experiential knowledge, and the widespread search for medicinal recipes in early modern Europe. Case studies of renowned healers Dorothea of Mansfeld and Anna of Saxony then demonstrate the value their pharmacy held in their respective roles as elderly widow and royal consort, while a study of the long-suffering Duchess Elisabeth of Rochlitz emphasizes the importance of experiential knowledge and medicinal remedies to the patient's experience of illness." --Publisher's description.
- Parallel imports of pharmaceuticals : evidence from Scandinavia and policy proposals from SWitzerland2008 Springerby Cédric Julien Poget.
- PAT applied in biopharmaceutical process development and manufacturing : an enabling tool for quality-by-design2012 CRCnetBASEedited by Cenk Undey, Duncan Low, Jose C. Menezes, Mel Koch."This book summarizes the state of the art in process analytical technologies applied to various aspects of biopharmaceutical process development and manufacturing. The text summarizes regulatory perspectives, FDA/EMEA guidelines, and new expectations. In addition, it explores new technology, especially in the area of real-time monitoring for end-point control as well as new sensor and analytical technologies. It details established and emerging measurement technologies, including future needs and challenges that require further research. The authors also present successful industrial-scale deployment case studies and strategies from the biopharmaceutical industry and discuss future trends"-- Provided by publisher.
- 2013 ScienceDirectFederico Goodsaid, William B. Mattes.The Path from Biomarker Discovery to Regulatory Qualification is a unique guide that focuses on biomarker qualification, its history and current regulatory settings in both the US and abroad. This multi-contributed book provides a detailed look at the next step to developing biomarkers for clinical use and covers overall concepts, challenges, strategies and solutions based on the experiences of regulatory authorities and scientists. Members of the regulatory, pharmaceutical and biomarker development communities will benefit the most from using this book-it is a complete and practical guide to biomarker qualification, providing valuable insight to an ever-evolving and important area of regulatory science. Contains a collection of experiences of different groups taking different types of biomarkers to different levels of qualification and provides insightful case studies of an important area of regulatory science Focuses on practical advice, concepts, strategies and overall outcomes to support those working toward biomarker qualification for clinical use Offers a valuable resource for members of the regulatory, pharmaceutical and biomarker development communities.
- 2014 SpringerDaniel Bar-Shalom, Klaus Rose, editors.As the first book that specifically addresses pediatric formulations in the context of drug development, Pediatric Formulations: A Roadmap covers anatomy and physiology of children as well as the technical state of the art, gives hints about where to find inspiration, and provides a suitable background on the regulatory framework. Existing books on pediatric formulations mainly discuss compounding at the pharmacy. This is not a "how to formulate" textbook for pharmaceutical scientists; the subtitle "A Roadmap" indicates that we are on a path in largely unexplored territory. It is an attempt to equip the reader with necessary information on how to get started with the appropriate mindset. Among medicinal specialties, pediatrics is a young discipline. The potential dangers of medicine were often underestimated in earlier times. Cough suppressants labeled as "suitable for children and adults" a hundred years ago could kill children as they contained opioids. Since then, a complex framework has evolved, with physicians, pharmacists, drug development companies, generic companies, academic scientists, regulatory authorities, reimbursement organizations, patients and children's parents as key players. The position of children in our society has changed dramatically during the last century. Children were protected against clinical trials, yet thanks to clinical trials, many more children with cancer survive today. The development of age-adjusted drug formulations is not only a technical challenge. For new drugs today, there are laws both in the United States and the European Union that compel the research-based pharmaceutical industry to also consider children during drug development. One of the major demands of authorities is the development of age-appropriate formulations.
- 2005 CRCnetBASEedited by Robert L. Bronaugh, Howard I. Maibach.Also available: Print – 2005
- Percutaneous penetration enhancers chemical methods in penetration enhancement. drug manipulation strategies and vehicle effects2015 SpringerNina Dragicevic, Howard I. Maibach, editors.
- 2006 CRCnetBASEedited by Eric W. Smith, Howard I. Maibach.
- Pharmaceutical accumulation in the environment : prevention, control, health effects, and economic impact2014 CRCnetBASEedited by Walter E. Goldstein.1. Introduction / Walter E. Goldstein -- 2. An insight into the discovery of the contamination of the environment and drinking water by pharmaceuticals / Thomas Heberer -- 3. Presence and fate of pharmaceuticals in the environment and in drinking water / James S. Smith Jr. -- 4. Occurrence, effects, and methods for antibiotics and illicit drugs in the environment / Tammy Jones-Lepp -- 5. Detection of pharmaceuticals in the environment : history of use as a forensic tool / Keir Soderberg and Remy J.-C. Hennet -- 6. Health impact of pharmaceuticals in the environment and in drinking water : potential for human and environmental risk / James S. Smith Jr. -- 7. Health impact of pharmaceuticals in the environment and in drinking water : analysis and research needs / Walter E. Goldstein -- 8. Effect of antibiotics on biological wastewater treatment processes / Olivier Potier, Jean-Noël Louvet, Christophe Merlin, Marie-Noëlle Pons, Dominique Dumas, and Walter E. Goldstein -- 9. Wastewater pharmaceuticals minimization : analysis of opportunities and costs / Walter E. Goldstein -- 10. Conclusions and recommendations, research opportunities, and implementation of measures to control environmental pharmaceuticals / Walter E. Goldstein.
- 2006 CRCnetBASEedited by Michael J. Groves.
- 2006 CRCnetBASEOle Pederson.
- 2012 SpringerRaymond A. Huml.Introduction to Competitive Intelligence -- Overall Perspective of Due Diligence Investigations and Processes -- The Regulatory Functional Review: Primary Roles -- The On-Site Due Diligence/Data Room Meeting and Interactions with Other Functional Area Experts -- Intellectual Property -- The Final Report -- Competitive Intelligence Summary.
- 2005 CRCnetBASEedited by Jennifer Dressman, Johannes Kramer.
- 2006 CRCnetBASEN. Anthony Armstrong.Introduction to experimental design -- Comparison of mean values -- Nonparametric methods -- Regression and correlation -- Multivariate methods -- Factorial design of experiments -- Response-surface methodology -- Model-dependent optimization -- Sequential methods and model-independent optimization -- Experimental designs for mixtures -- Artificial neural networks and experimental design.
- 2007 CRCnetBASESimon Gaisford, Michael A.A. O'Neill.
- 2006 CRCnetBASEedited by Joseph T. Piechocki, Karl Thoma.
- 2006 CRCnetBASEedited by Michael Levin.
- 2005 CRCnetBASEMark Paich, Corey Peck, and Jason Valant.
- 2008 ebrary2008 CRCnetBASEedited by Tony Kennedy.Strategic project management at the project level / Tony Kennedy -- Strategic project management at the portfolio level / Kevin Bilyard and Des Markland -- Project planning : from basic concepts to systems application / Carl A. Kutzbach, Carole Strong, and Sylvia Walker -- Project management of chemical, analytical, and formulation development / Dieter Krimmer -- Project management in exclusive synthesis / Lukas M.J. von Hippel -- Clinical trials--can they be project managed? / Les Rose -- Regulatory project management / Nicholas Wells -- Teams / Ralph White -- Project management and outsourcing drug development / Jon Court and Mark Fowler -- The project management function / Tony Kennedy.Also available: Print – 2008
- 2015 SpringerReem K. Al-Essa, Mohammed Al-Rubaie, Stuart Walker, Sam Salek.1. Overview of Medicines Regulatory Systems in the Gulf Region -- 2. The Regulatory Review Process in the Gulf Region -- 3. Regulatory Review Times in the Gulf Region -- 4. Quality Measures in the Gulf Regulatory Practices -- 5. The Current Status of the Common Technical Document -- 6. The Current Status of Drug Safety and Pharmacovigilance -- 7. The Centralized Regulatory Review in the Gulf Region -- 8. The Gulf States Assessment and Experience With the Centralised Procedure -- 9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure -- 10. Proposal For an Improved Centralized Regulatory System -- 11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions -- 12. The Regulatory Dilemma in the Gulf Region: The Way Forward.
- 2005 CRCnetBASEedited by Ira R. Berry.
- 2010 Springeredited by Kim Huynh-Ba.Contains proceedings of the AAPS Stability Workshop.
- 2007 ProQuest Safari[edited by] Alex Dmitrienko, Christy Chuang-Stein, Ralph D'Agostino.Statistics in drug development by Christy Chuang-Stein and Ralph D'Agostino -- Modern classification methods for drug discovery by Kjell Johnson and William Rayens -- Model building techniques in drug discovery by Kimberly Crimin and Thomas Vidmar -- Statistical considerations in analytical method validation by Bruno Boulanger, Viswanath Devanaryan, Walthère Dewé, and Wendell Smith -- Some statistical considerations in nonclinical safety assessment by Wherly Hoffman, Cindy Lee, Alan Chiang, Kevin Guo, and Daniel Ness -- Nonparametric methods in pharmaceutical statistics by Paul Juneau -- Optimal design of experiments in pharmaceutical applications by Valerii Fedorov, Robert Gagnon, Sergei Leonov, and Yuehui Wu -- Analysis of human pharmacokinetic data by Scott Patterson and Brian Smith -- Allocation in randomized clinical trials by Olga Kuznetsova and Anastasia Ivanova -- Sample-size analysis for traditional hypothesis testing: concepts and issues by Ralph G. O'Brien and John Castelloe -- Design and analysis of dose-ranging clinical studies by Alex Dmitrienko, Kathleen Fritsch, Janson Hsu, and Stephen Ruberg -- Analysis of incomplete data by Geert Molenberghs, Caroline Beunckens, Herbert Thijs, Ivy Jansen, Geert Verbeke, Michael Kenward, and Kristen Van Steen -- Reliability and validity: Assessing the psychometric properties of rating scales by Douglas Faries and Ilker Yalcin -- Decision analysis in drug development by Carl-Fredrik Burman, Andy Grieve, and Stephen Senn.
- 2005 CRCnetBASEedited by Steven W. Baertschi.
- 2011 SpringerAnthony J. Hickey, Hugh D.C. Smyth.
- 2011 SpringerAlan H.B. Wu, Kiang-Teck J. Yeo, editors.
- 2013 Springer Protocolsedited by Federico Innocenti, Ron H.N. van Schaik.Pharmacogenomics : historical perspective and current status / Rosane Charlab and Lei Zhang -- Denaturing high-performance liquid chromatography for mutation detection and genotyping / Donna Lee Fackenthal [and others] -- Clinical SNP detection by the smartAmp method / Toshihisa Ishikawa and Yoshihide Hayashizaki -- MALDI-TOF mass spectrometry / Dirk van den Boom, Matthias Wjst, and Robin E. Everts -- TaqMan® drug metabolism genotyping assays for the detection of human polymorphisms involved in drug metabolism / Toinette Hartshorne -- Pyrosequencing of clinically relevant polymorphisms / Cristi R. King and Sharon Marsh -- Pharmacogenetics using Luminex® xMAP® technology : a method for developing a custom multiplex single nucleotide polymorphism mutation assay / Gonnie Spierings and Sherry A. Dunbar -- Use of linkage analysis, genome-eide association studies, and next-generation sequencing in the identification of disease-causing mutations / Eric Londin [and others] -- GoldenGate genotyping assay : custom design, processing, and data analysis / Anna González-Neira -- Genome-wide gene expression profiling, genotyping, and copy number analyses of acute myeloid leukemia using affymetrix geneChips. / Mathijs A. Sanders and Peter J.M. Valk -- Epigenetic techniques in pharmacogenetics / Sandra G. Heil -- Plasmid derived external quality controls for genetic testing / Tahar van der Straaten and Henk-Jan Guchelaar -- Allelic imbalance assays to quantify allele-specific gene expression and transcription factor binding / Francesca Luca and Anna Di Rienzo -- SCAN : a systems biology approach to pharmacogenomic discovery / Eric R. Gamazon, R. Stephanie Huang, and Nancy J. Cox -- Methods to examine the impact of nonsynonymous SNPs on protein degradation and function of human ABC transporter / Toshihisa Ishikawa, Kanako Wakabayashi-Nakao, and Hiroshi Nakagawa -- In vitro identification of cytochrome P450 enzymes responsible for drug metabolism / Zhengyin Yan and Gary W. Caldwell -- In vitro and in vivo mouse models for pharmacogenetic studies / Amber Frick [and others] -- Hydrodynamic tail vein assay as a tool for the study of liver promoters and enhancers / Mee J. Kim and Nadav Ahituv -- Guide to the current web-based resources in pharmacogenomics / Dylan M. Glubb [and others] -- PharmGKB : the pharmacogenomics knowledge base / Caroline F. Thorn, Teri E. Klein, and Russ B. Altman -- Genetic databases in pharmacogenomics : the frequency of inherited disorders database (FINDbase) / Marianthi Georgitsi and George P. Patrinos -- Development of predictive models for estimating warfarin maintenance dose based on genetic and clinical factors / Lu Yang and Mark W. Linder -- Evidence based drug dosing and pharmacotherapeutic recommendations per genotype / Vera H.M. Deneer and Ron H.N. van Schaik.
- 2005 CRCnetBASEedited by Werner Kalow, Urs A. Meyer, Rachel F. Tyndale.Historical aspects of pharmacogenetics / Werner Kalow -- Pharmacogenomics and the promise of personalized medicine / Vural Ozdemir and Bernard Lerer -- Pharmacogenetics of drug metabolism: two clinically important polymorphic enzymes, CYP2D6 and TPMT / Georgios Panagiotidis and Leif Bertilsson -- Receptors / Wendell W. Weber -- Pharmacogenetics of drug transporters / Catia Marzolini, Rommel G. Tirona, and Richard B. Kim -- Variability in induction of human drug metabolizing enzymes / Allan B. Okey -- Pharmacogenetics and cardiac ion channels / Dan M. Roden -- Interethnic differences in drug response / Werner Kalow -- Clinical perspectives / Urs A. Meyer and David A. Flockhart -- Regulatory perspectives on pharmacogenomics / Lawrence J. Lesko and Janet Woodcock -- Tools of the trade: the technologies and challenges of pharmacogenetics / Glenn A. Miller -- Technologies for the analysis of single nucleotide polymorphisms - an overview / Denis M. Grant -- Molecular diagnostics / Tracy L. Stockley and Peter N. Ray --
- 2014 SpringerBrian R. Moyer, Narayan P.S. Cheruvu, Tom C.-C. Hu, editors.Advances in drugs and biologics to mitigate or cure some of nature's most complex medical problems have been incredible to behold. These accomplishments are due to the actions of a wide theatre of participants from biologists, pharmacologists, geneticists, chemists and manufacturers, molecular biologists, toxicologists, clinicians, nurses, program managers, quality assurance personnel, regulatory professionals and a new group of innovators the Imaging Scientists. Imaging has grown from the microscopy sections put on slides with special stains to now in vivo slices created with innovative physics, imaging tracers and contrast agents, and incredibly fast and accurate computational systems. The world of biology has become one of witnessing the actions of drugs and biologics through the window of mechanical and electrical engineering creating instruments and reporter molecules that can help us see into our bodies and paint them with medical information needed to resolve disease. This book will inspire imagination and elicit even more innovations in the development of new and novel drugs and biologics through imaging.
- 2015 SpringerYoo Keun Chan, Kwee Peng Ng, Debra Si Mui Sim, editors.This book is the 4th in a series of Acute Care books written with the aim to address the NEEDS of health care providers when handling the acutely ill patients. Globally it has become apparent that the study of pharmacology and subsequent clinical training has not always adequately equipped young doctors with the ability to administer drugs to their patients safely and confidently, particularly in the critically ill patient. Compounding this issue is the lack of resource material related to these pharmacological concepts contained in one book that can help health care providers to understand and manage drug therapy in the acute situation. In spite of progressively newer and more developed protocols, guidelines, algorithms and many other books addressing the technical aspects of what needs to be done, most health care providers still find it difficult to grasp the basic pharmacological knowledge and rationally deliver the CARE that is required in the acute phase of patient management. The editors/authors have therefore aimed for a book that highlights topics and pharmacological issues pertinent to management of patients in their hour of need. This is a multi-author book but the style has been guided by 3 editors. The editors have used a different perspective? that of normalizing abnormal physiological processes with pharmacological agents? to address the GAPS in a bedside to bench approach. The details are pared down but important principles/concepts are emphasized.
- 2014 SpringerPablo Avanzas, Peter Clemmensen, editors.Cardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series, and this particular title within the series, is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action, the possible adverse effects, and the management of patients prescribed these drugs.
- 2013 ClinicalKeyGeorge M. Brenner, Craig W. Stevens.Pharmacology, 4th Edition helps you master the "must-know" concepts in this subject and how they apply to everyday clinical problem solving and decision making. This concise yet comprehensive text clearly explains and illustrates challenging concepts and helps you retain the material - from course exams and the USMLE Step 1 right through to clinical practice. Quickly reference essential information thanks to abundant tables throughout, and drug classification boxes at the beginning of each chapter. See how pharmacology applies to practice with real-world case studies. Prepare for exams with self-assessment questions at the end of each chapter. Understand complex concepts visually with the aid of superb full-color illustrations. Access the complete contents online at www.studentconsult.com, along with an additional glossary, chapter-by-chapter summaries and case studies, a full list of featured drugs, 150 USMLE-style questions, animations, and more.
- 2006 ScienceDirectJonathan Merrills and Jonathan Fisher.
- 2015 SpringerZaheer-Ud-Din Babar, editor.Pharmacy Practice Research- Evidence and Impact -- Research Methodologies related to pharmacy practice: An Overview -- Quantitative Methods in Pharmacy Practice Research -- Qualitative Methods in Pharmacy Practice Research -- Action Research in Pharmacy Practice -- Participatory Action Research in Pharmacy Practice -- Mixed Methods Research in Pharmacy Practice -- Applying organizational theory in Pharmacy Practice Research -- Applying pharmacoeconomic methods in community and hospital pharmacy research -- Concept Mapping and pattern matching in pharmacy practice research -- Pharmacoepidemiological approaches in healthcare -- Future of Pharmacy Practice Research -- Pharmacists' attitudes towards pharmacy practice research: a review.
- 2014 ScienceDirectKamal Biswas.The pharmaceutical industry needs a shot in the arm - and not a moment too soon. The executive suite is mired in a bygone era, a time when extensive, well-funded pharmaceutical R & D produced blockbuster drugs, kept everything in-house and reaped the financial rewards. But that way of working needs to change. Executives now need to know what the technologists in their companies are doing in order to survive the next decade. Written for those new to industry, as well as for experienced professionals or specialists looking to expand their knowledge, this book is a must-read for business executive.
- 2014 SpringerFabrizio Benedetti, Paul Enck, Elisa Frisaldi, Manfred Schedlowski, editors.Due to the recent explosion of placebo research at many levels the Editors believe that a volume on Placebo would be a good addition to the Handbook of Experimental Pharmacology series. In particular, this volume will be built up on a meeting on Placebo which will be held in Tuebingen (Germany) in January 2013, and where the most prominent researchers in this field will present and exchange their ideas. The authors who will be invited to write chapters for this volume will be the very same speakers at this meeting, thus guaranteeing high standard and excellence in the topic that will be treated. The approach of the book is mainly pharmacological, including basic research and clinical trials, and the contents range from different medical conditions and systems, such as pain and the immune system, to different experimental approaches, like in vivo receptor binding and pharmacological/behavioral conditioning. Overall, the volume will give an idea of modern placebo research, of timely concepts in both experimental and clinical pharmacology, as well as of modern methods and tools in neuroscience.
- 2006 CRCnetBASEedited by Ijeoma F. Uchegbu, Andreas G. Schätzlein.
- 2017 intravenous medications : a handbook for nurses and health professionals. Thirty-three edition [33rd ed.] — Handbook of pharmaceutical analysis (100)
- Handbook of pharmaceutical granulation technology. 2nd ed. — Polymers in drug delivery (100)
- Practical pharmaceutics : an international guideline for the preparation, care and use of medicinal products — Write it down : guidance for preparing effective and compliant documentation. 2nd ed. (38)
- Harrison's Principles of Internal Medicine
- AAP Red Book Online
- Robbins & Cotran Pathologic Basis of Disease
- Sabiston Textbook of Surgery
- Nelson's Textbook of Pediatrics
- Surgical Exposures in Orthopaedics
- Mandell, Douglas, & Bennett's Principles & Practice of Infectious Diseases
- Red Book Online
- ICU Book
- Primary Care Medicine
- Campbell-Walsh Urology
Access restricted to Stanford community
Shortcut to Licensed Content
TO INSTALL, DRAG THIS BUTTON to your browser Bookmarks or Tools Bar.
Bookmark on Other Websites
- TO INSTALL, RIGHT CLICK this button.
- Select "Add to Favorites" (click “Continue” if you see a security alert)
- From the "Create in" menu, select “Favorites Bar” (IE8, IE9) to install
- Once installed it will look like this
- Click "Bookmark on Lane" to bookmark any webpage
- Your saved bookmark will appear on this page
Can't find it?
Look if we have it in print
- Springer Protocols
- Lange Series
- National Academy Press
- NCBI Bookshelf
- Thieme Atlases
A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more.
Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.MicroMedex: Premier pharmaceutical information source containing multiple databases and drug reference tools. Of particular value is DRUGDEX Evaluations, one of the most comprehensive drug sources available.DynaMed is a clinical information resource used by physicians to answer clinical questions quickly and easily at the point of care. Topics are updated daily as new evidence becomes available.Scopus is the largest abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings.A drug information resource containing: American Hospital Formulary System (AHFS), drug formulary for Lucile Packard Children's Hospital (LPCH) and Stanford Hospital & Clinics (SHC), Lexi-Drugs (adverse reactions, dosage and administration, mechanism of action, storage, use, and administration information), Lexi-Calc, Lexi-ID, Lexi-I.V. Compatibility (King Guide), Lexi-Interact, and Lexi-PALS.Cumulative Index to Nursing and Allied Health Literature (CINAHL) contains coverage of nursing and allied health literature.A knowledge database that provides access to topic reviews based on over 6000 clinically relevant articles. The evidence-based content, updated regularly, provides the latest practice guidelines in 59 medical specialtiesProvides critical assessments of systematic reviews compiled from a variety of medical journals.Selects from the biomedical literature original studies and systematic reviews that are immediately clinically relevant and then summarizes these articles in an enhanced abstract with expert commentary.
Multidisciplinary coverage of over 10,000 high-impact journals in the sciences, social sciences, and arts and humanities, as well as international proceedings coverage for over 120,000 conferences.
Includes cited reference searching, citation maps, and an analyze tool.
Features systematic reviews that summarize the effects of interventions and makes a determination whether the intervention is efficacious or not.
Cochrane reviews are created through a strict process of compiling and analyzing data from multiple randomized control trials to ensure comprehensiveness and reliability.Provides systematic coverage of the psychological literature from the 1800s to the present through articles, book chapters and dissertations.BMJ Clinical Evidence. A clinical information tool built around systematic reviews summarizing the current state of knowledge about prevention and treatment of clinical conditions.PIER (Physicians' Information and Education Resource) is a Web-based decision-support tool designed for rapid point-of-care delivery of up-to-date, evidence-based guidance for primary care physicians.Cochrane Central Register of Controlled Trials (CENTRAL) provides access to 300,000 controlled trials that have been identified the Cochrane Collaboration.Provides drug information targeted for patients.A continually updating drug monograph.The National Guideline Clearinghouse (NGC): A comprehensive database of evidence-based clinical practice guidelines and related documents.MedlinePlus: A repository of health information from the National Library of Medicine. Links are from trusted sites. No advertising, no endorsement of commercial companies or productsLPCH CareNotes via MicroMedex: Patient education handouts customized by LPCH clinical staffMicromedex Lab Advisor: Evidence based laboratory test informationA drug database organized by generic name, trade name and drug class.LPCH / Stanford Hospital Formulary.A goldmine of trusted consumer health information from the world's largest medical library.A trusted source of expert advice for and about kids, providing the information necessary to help patients and parents understand their unique needs.Provides patient handouts from the American Academy of Family Physician.Access to the Stanford Health Library for patients.Lane provides access to over 5,000 eBooks many of which provide helpful background material that will prepare you to better tackle primary literature.
Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities.
In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.
A web-based, decision support system for infectious diseases, epidemiology, microbiology and antimicrobial chemotherapy. The database, updated weekly, currently includes 337 diseases, 224 countries, 1,147 microbial taxa and 306 antibacterial (-fungal, -parasitic, -viral) agents and vaccines.
Over 10,000 notes outline the status of specific infections within each country.
Provides online, full-text access to Springer's journal titles as well as journals from other publishers.
Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.